Royal Bank of Canada’s Tourmaline Bio TRML Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-384
| Closed | -$18K | – | 7645 |
|
|
2025
Q3 | $18K | Sell |
384
-121,562
| -100% | -$3.37M | ﹤0.01% | 6257 |
|
|
2025
Q2 | $1.95M | Buy |
121,946
+120,464
| +8,128% | +$1.95M | ﹤0.01% | 3328 |
|
|
2025
Q1 | $23K | Sell |
1,482
-1,752
| -54% | -$28.1K | ﹤0.01% | 5874 |
|
|
2024
Q4 | $66K | Buy |
3,234
+790
| +32% | +$19.9K | ﹤0.01% | 5554 |
|
|
2024
Q3 | $63K | Buy |
2,444
+4
| +0.2% | +$67 | ﹤0.01% | 5593 |
|
|
2024
Q2 | $31K | Buy |
+2,440
| New | +$39.3K | ﹤0.01% | 5880 |
|
|
2023
Q3 | – | Sell |
-344
| Closed | -$10K | – | 7605 |
|
|
2023
Q2 | $10K | Buy |
344
+215
| +167% | +$5.49K | ﹤0.01% | 6488 |
|
|
2023
Q1 | $2K | Sell |
129
-232
| -64% | -$3.83K | ﹤0.01% | 6800 |
|
|
2022
Q4 | $4K | Buy |
361
+333
| +1,189% | +$5.35K | ﹤0.01% | 6802 |
|
|
2022
Q3 | $1K | Buy |
28
+15
| +115% | +$546 | ﹤0.01% | 7276 |
|
|
2022
Q2 | $1K | Sell |
13
-118
| -90% | -$9.31K | ﹤0.01% | 7210 |
|
|
2022
Q1 | $13K | Sell |
131
-336
| -72% | -$31.4K | ﹤0.01% | 6844 |
|
|
2021
Q4 | $72K | Buy |
467
+374
| +402% | +$55.3K | ﹤0.01% | 6162 |
|
|
2021
Q3 | $12K | Buy |
93
+32
| +52% | +$4.38K | ﹤0.01% | 6909 |
|
|
2021
Q2 | $9K | Buy |
+61
| New | +$9.34K | ﹤0.01% | 6922 |
|
Royal Bank of Canada's TRML Position: Q4 2025 in Review
Royal Bank of Canada sold out of Tourmaline Bio (TRML) in Q4 2025, closing a stake of 384 shares — an estimated $18K sold.
Royal Bank of Canada first reported a position in TRML in Q2 2021 and held it in 15 quarters. The position peaked at $1.95M in Q2 2025. 0 funds tracked by Wall St. Rank hold TRML as of Q4 2025.
- Royal Bank of Canada reported no remaining Tourmaline Bio position as of Q4 2025 after selling out during the quarter.
- Royal Bank of Canada sold 384 Tourmaline Bio shares in Q4 2025, an estimated $18K.
- Royal Bank of Canada first reported a position in Tourmaline Bio in Q2 2021 and held it in 15 quarters.
- Royal Bank of Canada's Tourmaline Bio position peaked at $1.95M in Q2 2025.
- 0 funds tracked by Wall St. Rank held Tourmaline Bio as of Q4 2025.
Based on Royal Bank of Canada's 13F filing for Q4 2025, filed 17 Feb 2026.